Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 33,300
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 34%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno...

Industry: Biotechnology
Sector: Healthcare
Address:
6 Heddon Street, London, United Kingdom
Northeast14
Northeast14 Jan. 22 at 8:19 AM
$GENFF one day people will understand what Glenflow are all about
0 · Reply
Northeast14
Northeast14 Jan. 20 at 5:42 PM
$GENFF let’s go Longevity
0 · Reply
Northeast14
Northeast14 Dec. 13 at 8:26 PM
$GENFF let’s go!!
0 · Reply
Northeast14
Northeast14 Dec. 12 at 3:26 PM
$GENFF let’s go Bad Boy!!
0 · Reply
Northeast14
Northeast14 Nov. 11 at 6:56 PM
$GENFF most undervalued stock around
0 · Reply
Northeast14
Northeast14 Nov. 4 at 9:00 PM
$GENFF only the strong will prosper. Patience pays off
0 · Reply
Northeast14
Northeast14 Oct. 22 at 6:38 AM
$GENFF they know it’s going to work! €2,808,175.92 recoverable advance, repayable to the Wallonia region upon commercialisation GF-1002 for use in treating MASH
0 · Reply
Northeast14
Northeast14 Oct. 22 at 6:28 AM
$GENFF Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that it has received official confirmation of €4,026,525 in non-dilutive financial support from the Wallonia region. The funds will support the ongoing development of Genflow's lead gene therapy, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe and progressive liver disease
0 · Reply
Northeast14
Northeast14 Oct. 14 at 5:44 PM
$LLY Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of the impact of its blockbuster drugs for diabetes and obesity on the use of health-care resources. The Indianapolis-based drugmaker’s investment includes as much as £204 million to establish a Lilly Gateway Labs location in the UK, according to an emailed statement Monday, giving early-stage biotechs access to Lilly’s expertise, lab space and potential financial investment. I WONDER IF THIS WILL BE INTO $GENFF
1 · Reply
Northeast14
Northeast14 Oct. 14 at 3:35 PM
0 · Reply
Latest News on GENFF
No data available.
Northeast14
Northeast14 Jan. 22 at 8:19 AM
$GENFF one day people will understand what Glenflow are all about
0 · Reply
Northeast14
Northeast14 Jan. 20 at 5:42 PM
$GENFF let’s go Longevity
0 · Reply
Northeast14
Northeast14 Dec. 13 at 8:26 PM
$GENFF let’s go!!
0 · Reply
Northeast14
Northeast14 Dec. 12 at 3:26 PM
$GENFF let’s go Bad Boy!!
0 · Reply
Northeast14
Northeast14 Nov. 11 at 6:56 PM
$GENFF most undervalued stock around
0 · Reply
Northeast14
Northeast14 Nov. 4 at 9:00 PM
$GENFF only the strong will prosper. Patience pays off
0 · Reply
Northeast14
Northeast14 Oct. 22 at 6:38 AM
$GENFF they know it’s going to work! €2,808,175.92 recoverable advance, repayable to the Wallonia region upon commercialisation GF-1002 for use in treating MASH
0 · Reply
Northeast14
Northeast14 Oct. 22 at 6:28 AM
$GENFF Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that it has received official confirmation of €4,026,525 in non-dilutive financial support from the Wallonia region. The funds will support the ongoing development of Genflow's lead gene therapy, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe and progressive liver disease
0 · Reply
Northeast14
Northeast14 Oct. 14 at 5:44 PM
$LLY Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of the impact of its blockbuster drugs for diabetes and obesity on the use of health-care resources. The Indianapolis-based drugmaker’s investment includes as much as £204 million to establish a Lilly Gateway Labs location in the UK, according to an emailed statement Monday, giving early-stage biotechs access to Lilly’s expertise, lab space and potential financial investment. I WONDER IF THIS WILL BE INTO $GENFF
1 · Reply
Northeast14
Northeast14 Oct. 14 at 3:35 PM
0 · Reply
Northeast14
Northeast14 Oct. 14 at 3:15 PM
$ALT money into $GENFF
3 · Reply
Northeast14
Northeast14 Oct. 14 at 2:23 PM
$LBPH money into $GENFF
0 · Reply
Northeast14
Northeast14 Oct. 11 at 7:51 PM
$ALT take a look at $GENFF
1 · Reply
Northeast14
Northeast14 Oct. 11 at 6:30 PM
$LLY have a look at $GENFF under the radar stock. 70/80% of RND funded by grants
0 · Reply
Northeast14
Northeast14 Oct. 11 at 6:26 PM
$GENFF under the radar and cheap! 70/80% of RND funded by grants! $ALT investors should be looking at the cheap $GENF stock
1 · Reply
Northeast14
Northeast14 Oct. 11 at 6:23 PM
$GENFF going into MASH trials next year. Cheap tickets $ALT
0 · Reply
Northeast14
Northeast14 Oct. 11 at 6:11 PM
$CVKD get the bargain $GENFF tickets!!
0 · Reply
Northeast14
Northeast14 Oct. 11 at 6:03 PM
$TWG get into $GENFF under the radar and due a huge move
0 · Reply
Northeast14
Northeast14 Oct. 11 at 5:01 PM
$NUVB take a look at $GENFF under the radar and under valued
0 · Reply
Northeast14
Northeast14 Oct. 11 at 2:14 PM
$TFFP have a look at $GENFF cheap tickets
0 · Reply
Northeast14
Northeast14 Oct. 11 at 2:13 PM
0 · Reply
Northeast14
Northeast14 Oct. 10 at 8:10 PM
@GregoryOnlyGains look into $GENFF an absolute bargain
1 · Reply